Indication
For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Medicine details

Medicine name:
patisiran (Onpattro)
SMC ID:
SMC2157
Pharmaceutical company
Alnylam Pharmaceuticals
BNF chapter
Submission type
Full
Status
Advice due date:
10 June 2019
SMC meeting date:
07 May 2019